Maze Therapeutics Reports Q3 2026 GAAP EPS of -$0.79 and Increased Net Loss
Maze Therapeutics (MAZE) reported its third-quarter financial results, highlighting a widening net loss of $48.0 million compared to $30.1 million in the same period last year. The company's GAAP earnings per share stood at -$0.79 for the quarter. The increase in losses was primarily driven by a significant 59.7% year-over-year rise in research and development expenses, which reached $40.2 million. Despite the increased spending, the company strengthened its liquidity position, reporting $477.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
Tickers: $MAZE
Topics: cash position earnings report net loss R&D expenses
Read the full article at Seeking Alpha
Part of the story St. Joe Reports Q3 GAAP EPS of $0.65 and Revenue of $156.2 Million (30 articles)